HUTCHMED Highlights Data to be Presented at ESMO

Summary by AI BETAClose X

HUTCHMED announced that new clinical data from studies of its compounds will be presented at the European Society for Medical Oncology (ESMO) Congress 2025. The data includes results from the FRUSICA-2 registration study of fruquintinib and sintilimab combination as a second-line treatment for locally advanced or metastatic renal cell carcinoma. Further analyses of the fruquintinib FRUSICA-1 study in endometrial cancer and the savolitinib SACHI and SAVANNAH studies in non-small cell lung cancer will also be presented. These presentations will cover various aspects of fruquintinib, savolitinib and surufatinib in different cancer types and treatment settings.

Disclaimer*

UK 100

Latest directors dealings